Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
European Firms Combat Antibiotic Resistance
by Michael McCoy
May 28, 2012
| A version of this story appeared in
Volume 90, Issue 22
Europe’s Innovative Medicines Initiative is launching a $281 million program in which academics and five drug companies will tackle the growing problem of antibiotic resistance. IMI, a public-private partnership, will provide $137 million of the funding, and the five companies—GlaxoSmithKline, AstraZeneca, Janssen, Sanofi, and Basilea Pharmaceutica—will provide the rest. Among the program’s goals are better-designed clinical trials for testing experimental antibiotics against resistant bacteria such as Staphylococcus aureus. IMI says Europe saw 25,000 deaths in 2007 due to antimicrobial resistance.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter